Transl Stroke Res. 2026 Jan 21;17(1):17. doi: 10.1007/s12975-025-01401-w.
ABSTRACT
Ischemic stroke is a common and devastating disease that imposes a huge burden on global health and the economy. Mitochondrial dysfunction is a key feature of cerebral ischemia-reperfusion injury (CIRI). Mitochondrial transplantation, an emerging neuroprotective strategy that introduces exogenous mitochondria into a living organism, has shown great potential in various neurological diseases. However, significant challenges persist, including the lack of standardized dosing regimens and unclear mechanisms regarding long-term mitochondrial engraftment. While initial clinical trials have demonstrated the safety of this approach, the field is currently at a pivotal juncture requiring rigorous translation from preclinical success to proven clinical efficacy. This review summarizes the in vitro and in vivo research findings on mitochondrial transplantation in stroke models, with the aim of providing a basis for the clinical translation of this technology.
PMID:41563620 | DOI:10.1007/s12975-025-01401-w